Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Shanghai Green Valley Surprises with China Approval for Alzheimer's Treatment

publication date: Nov 4, 2019

Shanghai Green Valley Pharma announced China approval of Oligomannate, a seaweed-based treatment for Alzheimer's disease that improves cognitive function. In a China clinical trial, patients who received Oligomannate showed a mean gain of 2.54 in their ADAS-Cog12 Scores, a result that was consistent from the first month to the end of the treatment at nine months. Oligomannate, a low molecular acid oligosaccharide compound extracted from marine brown algae, is the first new treatment for Alzheimer's globally since 2003, and also one of the first approved drugs that works by modifying the gut microbiome. Green Valley will launch the drug in China before the end of 2019 and start global Phase III trials next year to support approval in the US, Europe and Asia. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
August 25-27, 2020
China Standard Time
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China